The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugates (ADCs) Market Research Report 2024
Synopsis
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
The global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates (ADCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates (ADCs).
Report Scope
The Antibody Drug Conjugates (ADCs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates (ADCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates (ADCs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Segment by Type
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugates (ADCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
The global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates (ADCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates (ADCs).
Report Scope
The Antibody Drug Conjugates (ADCs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates (ADCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates (ADCs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Segment by Type
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugates (ADCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Seattle Genetics Technology
1.2.3 ImmunoGen Technology
1.2.4 Immunomedics Technology
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugates (ADCs) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2019-2030)
2.2 Antibody Drug Conjugates (ADCs) Growth Trends by Region
2.2.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody Drug Conjugates (ADCs) Historic Market Size by Region (2019-2024)
2.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Region (2025-2030)
2.3 Antibody Drug Conjugates (ADCs) Market Dynamics
2.3.1 Antibody Drug Conjugates (ADCs) Industry Trends
2.3.2 Antibody Drug Conjugates (ADCs) Market Drivers
2.3.3 Antibody Drug Conjugates (ADCs) Market Challenges
2.3.4 Antibody Drug Conjugates (ADCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue
3.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2019-2024)
3.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2019-2024)
3.2 Global Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
3.4 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates (ADCs) Revenue in 2023
3.5 Antibody Drug Conjugates (ADCs) Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugates (ADCs) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugates (ADCs) Breakdown Data by Type
4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2019-2024)
4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2025-2030)
5 Antibody Drug Conjugates (ADCs) Breakdown Data by Application
5.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2019-2024)
5.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2019-2030)
6.2 North America Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2019-2024)
6.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2019-2030)
7.2 Europe Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2019-2024)
7.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size (2019-2030)
8.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugates (ADCs) Market Size (2019-2030)
9.2 Latin America Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2019-2024)
9.4 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2019-2030)
10.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Antibody Drug Conjugates (ADCs) Introduction
11.1.4 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antibody Drug Conjugates (ADCs) Introduction
11.2.4 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Antibody Drug Conjugates (ADCs) Introduction
11.3.4 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Genmab
11.4.1 Genmab Company Detail
11.4.2 Genmab Business Overview
11.4.3 Genmab Antibody Drug Conjugates (ADCs) Introduction
11.4.4 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.4.5 Genmab Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Antibody Drug Conjugates (ADCs) Introduction
11.5.4 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.5.5 Bayer Recent Development
11.6 Seattle Genetics
11.6.1 Seattle Genetics Company Detail
11.6.2 Seattle Genetics Business Overview
11.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Introduction
11.6.4 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.6.5 Seattle Genetics Recent Development
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Company Detail
11.7.2 Takeda Pharmaceuticals Business Overview
11.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Introduction
11.7.4 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.7.5 Takeda Pharmaceuticals Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Antibody Drug Conjugates (ADCs) Introduction
11.8.4 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.8.5 AbbVie Recent Development
11.9 AbGenomics
11.9.1 AbGenomics Company Detail
11.9.2 AbGenomics Business Overview
11.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Introduction
11.9.4 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.9.5 AbGenomics Recent Development
11.10 ADC Therapeutics
11.10.1 ADC Therapeutics Company Detail
11.10.2 ADC Therapeutics Business Overview
11.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Introduction
11.10.4 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.10.5 ADC Therapeutics Recent Development
11.11 Astellas Pharma
11.11.1 Astellas Pharma Company Detail
11.11.2 Astellas Pharma Business Overview
11.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Introduction
11.11.4 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.11.5 Astellas Pharma Recent Development
11.12 Kairos Therapeutics
11.12.1 Kairos Therapeutics Company Detail
11.12.2 Kairos Therapeutics Business Overview
11.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Introduction
11.12.4 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2019-2024)
11.12.5 Kairos Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
